Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood, and Aging Diseases (R21)

The summary for the Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood, and Aging Diseases (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood, and Aging Diseases (R21): This funding opportunity announcement (FOA) solicits Exploratory/Developmental (R21) grant applications from applicant organizations that propose to define the factors and mechanisms controlling the differentiation of embryonic or adult stem or progenitor cells, either in vitro or in vivo. It is designed to stimulate new scientific advances in stem cell differentiation including technology research that may not be hypothesis driven. The long range goal of this program is the development of methods to direct the differentiation or development of stem cells along specific cell lineages to yield replacement cells for clinical use, whether the replacement cells are formed in vitro for delivery or formed in vivo in the tissue or organ environment. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -This FOA will utilize the Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOAs of identical scientific scope, PA-06-124, that solicits applications under the SBIR [R43/R44] mechanism and PA-06-125, that solicits applications under the STTR [R41/R42] mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations: For profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals and laboratories; Units of State government; Units of local government; Eligible institutions of the Federal government; Domestic institutions; Foreign institutions; Faith-based or community-based organizations; Indian/Native American Tribal Governments (Federally Recognized); Indian/Native American Tribal Governments (Other than Federally Recognized); and Indian/Native American Tribally Designated Organizations. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.